Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan

Okazaki, Morihiro; Kobayashi, Hisanori; Shimizu, Hirohito; Ishii, Yutaka; Yajima, Tsutomu; Kanbori, Masayoshi

doi:10.1007/s40744-018-0101-y

Cited by 10 publications

(11 citation statements)

References 50 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of patients with severe radiographic progression has decreased over the last decades due to younger age at diagnosis and the development of several therapeutic agents. However, in a percentage of patients, prevention of severe radiographic progression remains a challenge due to inadequate treatment response or adverse events associated with therapeutic agents (1,2). Furthermore, previous studies demonstrated that anti-citrullinated protein antibodies (ACPAs) and the presence of HLA-region genes were associated with bone destruction, but their predictive accuracy was not sufficient (3)(4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis

Honda

Ikari

Yano

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective To investigate whether polygenic risk scores obtained using data from a genome‐wide association study (GWAS) of rheumatoid arthritis (RA) susceptibility can be predictors of radiographic progression. Methods We constructed polygenic risk scores using GWAS summary data on associations of single‐nucleotide polymorphisms with RA susceptibility. The polygenic risk scores were stratified into quintiles based on levels of significance (ranging from top quintile of polygenic risk scores to bottom quintile). In addition, change in the Sharp/van der Heijde score (SHS) of radiographic progression over the first 5 years after onset of RA was assessed. The change in SHS over 5 years was stratified according to quartiles, with the top quartile of change in SHS defined as severe radiographic progression (score change of >35 points) and the remaining 3 quartiles defined as nonsevere radiographic progression. Polygenic risk scores were assessed for their ability to predict the SHS status over 5 years in a training set (n = 500 RA patients) for selection of the best model, and in a testing set (n = 740 RA patients) for validation of the data. We evaluated the performance of the polygenic risk score as a predictor of severe radiographic progression in univariable and multivariable analyses with inclusion of other factors. Results Polygenic risk scores constructed from 43,784 single‐nucleotide polymorphisms significantly differed between patients who experienced severe radiographic progression and those with nonsevere radiographic progression in both the training set (P = 0.0064) and the testing set (P = 0.017). Patients with polygenic risk scores in the top quintile had a higher risk of severe progression compared to those with polygenic risk scores in the bottom quintile (odds ratio [OR] 1.90, P = 0.0022), and the risk of severe radiographic progression was even higher when restricted to patients who were younger at disease onset (OR 5.06, P = 0.00038). The group with polygenic risk scores in the top quintile and the anti–citrullinated protein antibody (ACPA)–positive group had significantly higher proportions of patients with severe radiographic progression (P = 0.00052 and P = 0.0022, respectively) compared to the remaining groups. Multivariable analysis showed that polygenic risk score (P = 0.00019) as well as female sex (P = 0.0033), ACPA positivity (P = 0.0023), and body mass index (P = 0.024) were independent risk factors for severe radiographic progression. Conclusion A polygenic risk score that is derived from GWAS data on RA susceptibility is associated with the level of severity of radiographic progression in patients with RA.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis

Honda

Ikari

Yano

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…In Japan, the GO-FORTH (5) and GO-MONO (6) trials demonstrated the clinical efficacy and safety of GLM in combination with MTX and as monotherapy, respectively. Based on these data, the Japanese Pharmaceuticals and Medical Devices Agency approved GLM (50 and 100 mg) as the fourth anti-TNF-α antibody in 2011 (7); the 100 mg dose is only available in Japan (8).…”

Section: Introductionmentioning

confidence: 99%

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis

et al. 2021

View full text Add to dashboard Cite

Objective To evaluate the effectiveness and drug retention rate of golimumab (GLM) for long-term use in daily practice for patients with rheumatoid arthritis (RA). Methods Patients with RA who started GLM therapy with a minimum follow-up period of 52 weeks were included. The patients were divided into a biologic-naïve group and switch group. The disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) (DAS28-ESR), grip power, and Japanese version of the health assessment questionnaire (J-HAQ) score were assessed. In addition, the treatment continuation rate was evaluated at the final follow-up. Patients Sixty-five patients (58 women and 7 men; median [range] age, 69 [61-74] years; median [range] disease duration, 9 [5-16] years) were included. Twenty-eight patients were biologic-naïve (naïve group), and 37 were switched to biologics (switch group). Results The median (range) follow-up period was 134 (58-162) weeks. The DAS28-ESR improved from a median (range) of 4.31 (3.52-5.25) to 2.65 (2.28-3.77) in the naïve group and from 4.27 (3.19-4.89) to 2.89 (2.49-3.88) in the switch group. The grip power improved in both groups (p<0.01); however, the J-HAQ score showed no marked improvement in either group. The continuation rates were 22/28 (78.6%) in the naïve group, and 26/37 (70.3%) in the switch group at the final follow-up. Conclusion We herein report for the first time that the long-term use of GLM improves the grip power. Improving the grip power may help prevent sarcopenia and frailty in the future. Given the efficacy and high continuation rate, we suggest that GLM would be a well-tolerated treatment option for RA.

show abstract

“…Geronsafety associates with elderly care, drug use, use of technology, home care services, production and design, medical field. Safety includes the protection of the environment against harmful effects of the technological devices with which elderly people communicate [4][5][6]. Harmful effects are divided into two as external and individual effects.…”

Section: Conceptual Frameworkmentioning

confidence: 99%

“…Aging research is increasing due to the increasing elderly population and these studies are socially prominent. The negative effects of biological and physical factors on aging have been replaced by social, psychological and psychosocial factors [1][2][3][4]. This is due to developing technology and innovations brought by the digital age.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Geronsafety

Özsungur¹

2019

BJSTR

View full text Add to dashboard Cite

Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan

Cited by 10 publications

References 50 publications

Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis

Association of Polygenic Risk Scores With Radiographic Progression in Patients With Rheumatoid Arthritis

Long-term Use of Golimumab in Daily Practice for Patients with Rheumatoid Arthritis

Geronsafety

Contact Info

Product

Resources

About